A 45-year-old woman with metastatic adenocarcinoma of the lung develops DIC with severe hypofibrinogenemia (fibrinogen 80 mg/dL) and active bleeding. After transfusion of fresh frozen plasma, her coagulopathy worsens. Which is the drug of choice to restore fibrinogen and improve hemostasis in this patient?
A. Platelet concentrate
B. Cryoprecipitate
C. Prothrombin complex concentrate
D. Fresh frozen plasma
Explanation
Fibrinogen Replacement in DIC
Key Point
Cryoprecipitate is the drug of choice for fibrinogen replacement in DIC because it provides concentrated fibrinogen with minimal volume and is more effective than FFP for raising fibrinogen levels rapidly.
Why Cryoprecipitate is Superior
1. Fibrinogen Concentration
Cryoprecipitate: 150–250 mg fibrinogen per unit (10 mL).
FFP: 1–2 g fibrinogen per unit (200–250 mL).
Cryoprecipitate delivers 10–15 times more fibrinogen per unit volume.
2. Volume Efficiency
Cryoprecipitate: 10 units (100 mL) raises fibrinogen by 100 mg/dL.
FFP: 10 units (2 L) raises fibrinogen by only 20 mg/dL.
In DIC with fluid overload risk, cryoprecipitate avoids pulmonary edema.
3. Composition of Cryoprecipitate
Table
Component
Amount per Unit
Clinical Benefit
Fibrinogen
150–250 mg
Restores clotting substrate
Factor VIII
80–100 IU
Supports intrinsic pathway
von Willebrand factor
150–250 IU
Improves platelet adhesion
Fibronectin
50–100 mg
Supports hemostasis
Factor XIII
50–100 IU
Stabilizes fibrin clot
High-YieldNEET PG
Cryoprecipitate is the ONLY product that should be used for isolated fibrinogen replacement; FFP is inefficient and causes volume overload.
Goal: Maintain fibrinogen >100 mg/dL (preferably >150 mg/dL) to support hemostasis.
Transfusion trigger: Fibrinogen <100 mg/dL with active bleeding or high risk of bleeding.
Dosing: 1 unit cryoprecipitate per 5–7 kg body weight raises fibrinogen by ~100 mg/dL.
Why FFP Failed in This Case
FFP contains fibrinogen but in dilute form; transfusing large volumes (10 units = 2 L) to raise fibrinogen adequately risks:
Pulmonary edema.
Dilutional coagulopathy (worsening thrombocytopenia and factor deficiency).
Hypervolemia in a patient already at risk for ARDS (adenocarcinoma + DIC).
Clinical Pearl
In DIC, the coagulation cascade is being consumed faster than FFP can replace it. Cryoprecipitate's concentrated fibrinogen allows rapid correction without volume overload, giving hemostasis a better chance while the underlying disease is treated.
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
